MyelofibrosisSymptoms, Doctors, Treatments, Advances & More
Myelofibrosis Overview
Learn About Myelofibrosis
View Main Condition: Myeloproliferative Neoplasms (MPN)
Myelofibrosis is a disorder of the bone marrow in which the marrow is replaced by fibrous scar tissue.
Idiopathic myelofibrosis; Myeloid metaplasia; Agnogenic myeloid metaplasia; Primary myelofibrosis; Secondary myelofibrosis; Bone marrow - myelofibrosis
Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that develop into all of your blood cells. Your blood is made of:
- Red blood cells (which carry oxygen to your tissues)
- White blood cells (which fight infection)
- Platelets (which help your blood clot)
When the bone marrow is scarred, it cannot make enough blood cells. Anemia, bleeding problems, and a higher risk for infections may occur.
As a result, the liver and spleen try to make some of these blood cells. This causes these organs to swell.
The cause of myelofibrosis is often unknown. There are no known risk factors. When it occurs, it often develops slowly in people over age 50. Women and men are equally affected. There is an increased occurrence of this condition in Ashkenazi Jews.
Blood and bone marrow cancers, such as myelodysplastic syndrome, leukemia, and lymphoma, may also cause bone marrow scarring. This is called secondary myelofibrosis.
Symptoms may include any of the following:
- Abdominal fullness, pain, or feeling full before finishing a meal (because of an enlarged spleen)
- Bone pain
- Easy bleeding, bruising
- Fatigue
- Increased likelihood of getting an infection
- Pale skin
- Shortness of breath with exercise
- Weight loss
- Night sweats
- Low grade fever
- Enlarged liver
- Dry cough
- Itchy skin
A bone marrow or stem cell transplant may improve symptoms, and may cure the disease. This treatment is usually considered for younger people.
Other treatment may involve:
- Blood transfusions and medicines to correct anemia
- Chemotherapy
- Targeted medicines
- Removal of the spleen (splenectomy) if swelling causes symptoms, or to help with anemia (rarely done)
Moffitt Cancer Center, Magnolia Campus
Jeffrey Lancet is a Hematologist practicing medicine in Tampa, Florida. Dr. Lancet is rated as an Elite provider by MediFind in the treatment of Myelofibrosis. He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Lancet is currently accepting new patients.
Atrium Health Levine Cancer Institute
Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Myelofibrosis. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.
Uke
Nicolaus Kroger practices practicing medicine in Hamburg, Germany. Kroger is rated as an Elite expert by MediFind in the treatment of Myelofibrosis. They are also highly rated in 36 other conditions, according to our data. Their clinical expertise encompasses Graft Versus Host Disease (GvHD), Myelofibrosis, Leukemia, Bone Marrow Transplant, and Bone Graft.
As the disease worsens, the bone marrow slowly stops working. Low platelet count leads to easy bleeding. Spleen swelling may get worse along with anemia.
The average survival of people with primary myelofibrosis is about 5 years. But some people survive for decades.
Complications may include:
- Development of acute myelogenous leukemia
- Infections
- Bleeding
- Blood clots
- Liver failure
Make an appointment with your provider if you have symptoms of this disorder. Seek medical care right away for uncontrolled bleeding, shortness of breath, or jaundice (yellow skin and whites of the eyes) that gets worse.
Summary: This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantati...
Summary: RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Published Date: May 01, 2026
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Gotlib J. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 152.
Tefferi A. Myeloproliferative neoplasms. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 97.
Venugopal S, Najfeld V, Keyzner A, Jamal SME, Hoffman R, Mascarenhas J. Primary myelofibrosis and chronic neutrophilic leukemia. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 72.

